New daily weight loss pill made patients lose more than 10% of their body weight
By Tracy Swartz
Needle-less to say, it’s effective!
Eli Lilly’s experimental GLP-1 pill caused participants in a late-stage trial to shed an average of 10.5% of their body weight — nearly 23 pounds — over 16 months, according to data released Tuesday.
The daily medication, known as orforglipron, has also been shown to reduce hemoglobin A1C —average blood sugar levels over the past two to three months — by 1.3% to 1.8% in people with diabetes.
Eli Lilly logo on a San Diego office building.
3
Eli Lilly’s experimental GLP-1 pill, orforglipron, caused participants in a late-stage trial to shed an average of 10.5% of their body weight over 16 months, according to new data.
REUTERS
Lilly plans to submit its full trial data for US regulatory approval for obesity by the end of the year, which would reshape a GLP-1 market dominated by injectables.
“If approved, we are ready to offer a convenient, once-daily pill that can be scaled globally — removing barriers and redefining how obesity is treated around the world,” Kenneth Custer, Lilly executive vice president and president of Lilly Cardiometabolic Health, said in a statement.
Explore More
An image collage containing 2 images, Image 1 shows Screenshot of a man in a car warning about the health risks of prolonged sitting, Image 2 shows Nurse assisting elderly man with paperwork at retirement home
This 'harmless' habit is the quickest way to end up in a nursing home when you're older, warns physical therapist
Woman stressed at work, woman peeing
Your pee can offer a hint about how you'll deal with stress today
An image collage containing 2 images, Image 1 shows Dr. Dendy Engelman in a red jumpsuit, Image 2 shows Dr. Dendy Engelman examines her mother, Deborah
I'm a cosmetic surgeon — skincare I actually use to look younger including a 'holy trinity' in the morning
In this latest trial, over 1,600 overweight diabetics received either orforglipron in 6-, 12- or 36-milligram (mg) doses or a placebo.
The participants took the pill once a day without food and water restrictions for 72 weeks.
Close-up of a man taking pills with water.
3
Several GLP-1 pill options are in the works as demand grows for these weight-loss and diabetes drugs.
InsideCreativeHouse – stock.adobe.com
The 36-mg dose brought the greatest weight loss, 10.5%, while the 12-mg dose group shed 7.8% of their body weight on average.
See Also
An image collage containing 3 images, Image 1 shows Injection pens and packaging boxes for Mounjaro, Wegovy, Ozempic, and Zepbound diabetes and weight-loss medications, Image 2 shows Woman's pelvis in white underwear with a pink flower over her crotch, Image 3 shows Close-up of a woman holding an insulin pen
‘Ozempic vulva’ is making women look aged and droopy down there
Those on 6 mg dropped 5.5% while placebo takers slimmed down 2.2% (just over 5 pounds).
Orforglipron users also saw improvements in their non-HDL “bad” cholesterol, systolic blood pressure and triglycerides, all significant factors for heart disease and stroke, Lilly said.
Like other GLP-1 treatments, top-reported side effects include nausea, vomiting, diarrhea, constipation and indigestion that were generally mild to moderate.
Some 10.6% of participants on the highest orforglipron dose stopped treatment due to side effects compared to 4.6% of placebo users.
Quitting GLP-1 medications — because of side effects, cost or supply troubles — is a major problem because people tend to regain the weight.
Woman injecting semaglutide.
3
The GLP-1 market is dominated by injectables like Ozempic.
millaf – stock.adobe.com
See Also
An international team of researchers has found more evidence that people booze a lot less when taking GLP-1 drugs like Ozempic. People drinking and a boxy of Wegovy are shown here.
How much less Irish people drank while taking weight loss drugs
GLP-1 drugs mimic the GLP-1 hormone the body naturally produces after eating, so users feel fuller for longer and don’t crave food as often.
The body’s natural hunger signals and previous metabolic slowdown typically return when the medication stops.
Most GLP-1 drugs are injectable. Novo Nordisk’s Rybelsus — which is made with semaglutide, the active ingredient in Ozempic — is a pill that has been approved for treating Type 2 diabetes in adults.
Other pills are in the works. The US Food and Drug Administration is reviewing Novo Nordisk’s application for an oral version of its popular weight-loss drug Wegovy.
Expect the market to swell as research reveals more promising applications for GLP-1 drugs beyond obesity and Type 2 diabetes.
Scientists are investigating their ability to reduce the risk of heart disease, kidney disease, neurodegenerative disorders, substance abuse and other chronic conditions.
Welcome to Billionaire Club Co LLC, your gateway to a brand-new social media experience! Sign up today and dive into over 10,000 fresh daily articles and videos curated just for your enjoyment. Enjoy the ad free experience, unlimited content interactions, and get that coveted blue check verification—all for just $1 a month!
Account Frozen
Your account is frozen. You can still view content but cannot interact with it.
Please go to your settings to update your account status.
Open Profile Settings